PDCD1 and non-small cell lung carcinoma: Furthermore, in a phase I/II trial (NCT02608268), MGB453 (an anti-TIM3 agent) was assessed in combination with PDR001 (an anti-PD-1 therapy) for advanced solid cancers, including NSCLC and melanoma.